UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000020865
Receipt number R000023963
Scientific Title Comparison of postoperative administration between dienogest and ultra low dose estrogen and progesterone tablet for suppressing recurrence of ovarian endometriomas: A randomized study
Date of disclosure of the study information 2016/03/01
Last modified on 2019/09/02 16:40:17

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Comparison of postoperative administration between dienogest and ultra low dose estrogen and progesterone tablet for suppressing recurrence of ovarian endometriomas: A randomized study

Acronym

Comparison of postoperative administration between dienogest and ultra low dose estrogen and progesterone tablet for suppressing recurrence of ovarian endometriomas: A randomized study

Scientific Title

Comparison of postoperative administration between dienogest and ultra low dose estrogen and progesterone tablet for suppressing recurrence of ovarian endometriomas: A randomized study

Scientific Title:Acronym

Comparison of postoperative administration between dienogest and ultra low dose estrogen and progesterone tablet for suppressing recurrence of ovarian endometriomas: A randomized study

Region

Japan


Condition

Condition

endometriosis (ovarian endometrioma)

Classification by specialty

Obstetrics and Gynecology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The purpose of this study is to test the efficacy and safety of dienogest and ultra low dose estrogen and progesterone tablet (LUNABELL tablets ULD) for suppressing recurrence of ovarian endometriomas after primary surgery. We sought to create clinical data and establish optimal treatment of postoperative ovarian endometriomas.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Phase IV


Assessment

Primary outcomes

Primary outcome is the recurrence rate 2 years after surgery.
The definition of recurrence is the presence of endometriomas more than 2 cm by transvaginal ultrasound on at least two consecutive examinations.
Follow-up visits and transvaginal ultrasound are scheduled every 3 months after commencement of treatment.
Pelvic MRI is performed when recurrence is suspected.

Key secondary outcomes

The patients are asked to score the intensity of pelvic pain at the follow-up visit using a visual analogue scale (VAS) score. Disease recurrence is defined as sequential increase of VAS score or increase of VAS score as high as preoperative score.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation

YES

Institution consideration

Institution is considered as adjustment factor in dynamic allocation.

Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

dienogest

1mg twice a day (2mg/day)
From menstrual cycle day 2-5
For 24 months

Interventions/Control_2

ultra low dose estrogen and progesterone tablet

1 tablet once a day (at the same time of each day)
From menstrual cycle day 2-5
After taking tablets for 21 days, patients stop it for 7 days. These 28 days is one cycle. Whether withdrawal bleeding stops or not, patients start to take the tablet from cycle day 29. It is repeated thereafter for 24 months.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

50 years-old >

Gender

Female

Key inclusion criteria

(a) Patients who had undergone laparoscopic surgery for ovarian endometriomas at Osaka University Hospital, Minoh City Hospital or Toyonaka Municipal Hospital
(b) Patients who consent to this study in writing
(c) Patients who do not want to become pregnant during this study period
(d) Patients more than 20 years old and not more than 50 years old

Key exclusion criteria

(a) undiagnosed genital bleeding
(b) pregnant, probably pregnant or lactating
(c) allergic to ingredient of dinagest tablets or LUNABELL tablets ULD
(d) patients who want to become pregnant
(e) estrogen dependent malignant tumor (e.g. breast cancer, endometrial cancer), cervical cancer or suspected to have those diseases
(f) thrombophlebitis, pulmonary embolism, cerebrovascular accident and coronary artery disease, or past history of those diseases
(g) more than 35 years old and smoke more than 15 cigarettes
(h) migraine with aura (e.g. fortification spectrum etc.)
(i) valvular disease with pulmonary; hypertension or atrial fibrillation valvular disease with past history of subacute infectious endocarditis
(j) diabetes with vascular disease (diabetic nephropathy, diabetic retinopathy etc.)
(k) primary cause of thrombosis
(l) antiphospholipid antibody syndrome
(m) within 4 weeks before surgery, within 2 weeks after surgery, within 4 weeks after delivery, or long-term bed rest
(n) severe liver damage
(o) liver tumor
(p) lipid metabolism abnormality
(q) hypertension (except mild hypertension)
(r) otosclerosis
(s) past history of jaundice, persistent pruritus or herpes during pregnancy
(t) probably in the middle of bone growth
(u) patients who are judged ineligible by doctor in charge for other reasons

Target sample size

120


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Tadashi Kimura

Organization

Osaka University Hospital

Division name

Department of Obstetrics and Gynecology

Zip code


Address

2-2, Yamadaoka, Suita, Osaka

TEL

06-6879-3351

Email

tadashi@gyne.med.osaka-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Mami Morikawa

Organization

Osaka University Graduate School of Medicine

Division name

Department of Obstetrics and Gynecology

Zip code


Address

2-2, Yamadaoka, Suita, Osaka

TEL

06-6879-3354

Homepage URL


Email

mami0204@gyne.med.osaka-u.ac.jp


Sponsor or person

Institute

Osaka University Hospital

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor

Minoh City Hospital
Toyonaka Municipal Hospital

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

大阪大学病院(大阪府)、箕面市立病院、市立豊中病院


Other administrative information

Date of disclosure of the study information

2016 Year 03 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2016 Year 01 Month 13 Day

Date of IRB

2016 Year 02 Month 12 Day

Anticipated trial start date

2016 Year 04 Month 01 Day

Last follow-up date

2023 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2016 Year 02 Month 03 Day

Last modified on

2019 Year 09 Month 02 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023963


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name